Abstract:
Focal segmental glomerulosclerosis (FSGS) is characterized by proteinuria and renal function decline, leading to chronic kidney disease (CKD) and end-stage renal disease (ESRD; Ref. 15). Approximately 55% of patients with idiopathic FSGS with high-grade proteinuria will proceed to ESRD at 10 yr following
diagnosis (40). The FSGS lesion can also develop as the end result of a spectrum of sources of glomerular injury, obesity, and reduced nephron mass. Despite current therapies including renin-angiotensin-aldosterone system (RAAS) inhibitors, antihypertensives, and immunosuppressants, clinical outcomes remain suboptimal.